Mathew Strasser, DO
Internal Medicine · North Kansas City, MONPI 1164447884
Payments from drug & device makers
Across 131 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$224
- GSK$193
- Lilly USA, LLC$179
- Otsuka America Pharmaceutical, Inc.$175
- Boehringer Ingelheim$175
- AstraZeneca$138
- plus $987 from 24 others
What the payments were for
- Food & beverage$2,01297%
- Education$593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $224 |
| GSK | 16 | $193 |
| Lilly USA, LLC | 12 | $179 |
| Otsuka America Pharmaceutical, Inc. | 11 | $175 |
| Boehringer Ingelheim | 11 | $175 |
| AstraZeneca | 8 | $138 |
| Exact Sciences | 6 | $104 |
| Lundbeck LLC | 4 | $86 |
| Pfizer | 5 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Amgen | 5 | $70 |
| Novo Nordisk | 4 | $66 |
| Abbott | 4 | $63 |
| Novartis | 4 | $63 |
| Sumitomo Pharma America, Inc. | 4 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $26 |
| Bayer | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Viiv Healthcare Company | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Biogen | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Edwards Lifesciences | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
How this compares
$2,071 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $199,908 |
| Humira(Cf) PenAdalimumab | 14 | $111,565 |
| XareltoRivaroxaban | 92 | $101,247 |
| JardianceEmpagliflozin | 69 | $79,850 |
| EliquisApixaban | 69 | $79,658 |
| MounjaroTirzepatide | 70 | $73,641 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $56,870 |
| MyrbetriqMirabegron | 41 | $31,843 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $27,552 |
| Repatha SureclickEvolocumab | 27 | $24,615 |
| TradjentaLinagliptin | 22 | $24,320 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $22,085 |
| TrulicityDulaglutide | 12 | $18,847 |
| FarxigaDapagliflozin Propanediol | 17 | $17,387 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $12,886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $66 | $199,908155 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $175 | $109,878103 claims |
| Johnson & JohnsonXarelto | $14 | $101,24792 claims |
| Lilly USA, LLCMounjaro, Trulicity | $179 | $92,48882 claims |
| PfizerEliquis, Abrysvo | $79 | $87,65197 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $193 | $68,744104 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $138 | $37,94751 claims |
| AbbVieSavella | $224 | $5,20311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in North Kansas City
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.